-- Genscript Biotech (HKG:1548) associate Legend Biotech said Carvykti generated around $597 million in net trade sales in the quarter ended March 31, according to a Tuesday Hong Kong bourse filing.
The sales were recorded under a collaboration and license agreement between Legend Biotech and Janssen Biotech dated Dec. 21, 2017.
Abundate (SGX:570) booked a loss of SG$320,000 in the fiscal second half ended Feb. 28, from a profit of SG$134,000 a year earlier, according to a Wednesday filing with the Singapore Exchange.Loss per share stood at SG$0.0031 compared with earnings per share of SG$0.0013 in the year-ago period.Revenue rose 6% year over year to SG$4.1 million from SG$3.9 million, backed by strong demand for local construction activities.